Project Grant R21AT013004
Award Date
9/13/24
Completion Date
8/31/26
Dollars Obligated
$5K
Funding Federal Agency
Fogarty International Center
Awarding Federal Agency
National Center for Complementary and Integrative Health
Federal Grant Program
93.989
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This federal Project Grant award, valued at $238,276, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding supports research at the University of California, Irvine to investigate the role of the enzyme N-acylethanolamine acid amidase (NAAA) in the development of hyperalgesic priming, a model for studying the transition from acute to chronic pain. The project aims to identify the receptor...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $118,457 to The Trustees of the University of Pennsylvania to conduct research aimed at harnessing the genetics of chronic pain to inform the development of non-addictive analgesic medications. The 4-year project, starting on April 15, 2025, will characterize the genetic architecture underlying chronic pain liability and addiction, estimate...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
This $675,107 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders supports research by Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) design and synthesize new cannabinoid CB1 receptor allosteric agonist-positive allosteric modulator (CB1R AGO-PAM) and CB2 receptor...
This $1,563,778 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279) on September 12, 2024. The grant supports research conducted by Duke University to develop equilibrative nucleoside transporter (ENT1) inhibitors as potential non-opioid pain therapeutics. The project aims to: 1) validate ENT1 as a novel target for neuropathic pain treatment, 2) characterize a novel ENT1 inhibitor compound...
This federal Project Grant award in the amount of $351,097 was provided by the National Institute of Neurological Disorders and Stroke (NINDS), which is part of the National Institutes of Health (NIH). The grant was awarded under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279) to establish a rigorous and supportive interdisciplinary training program in clinical pain research at Mass General Brigham (MGB) in Boston. The program will support a diverse pool of 8 postdoctoral...
This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
This Project Grant award, with a total funding amount of $664,772, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award supports research to investigate the signaling mechanisms involving the neurotensin receptor 2 (NTSR2) and voltage-gated calcium channels (Cav2.3 and Cav2.2) as a novel, non-opioid analgesic pathway for the...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...